Abstract
Early efforts to therapeutically target RAS focused away from the GTP-binding site because it was assumed that small molecule inhibitors could never compete with the picomolar binding affinity and micromolar cellular concentrations of GTP and achieve specificity for the RAS family members. Medicinal chemistry has evolved, providing new options for designing covalent compounds. Here, we review the theoretical basis for attempting to target the GTP-binding site of RAS using covalent chemistry and discuss proof-of-concept experiments.
Original language | English (US) |
---|---|
Title of host publication | Conquering RAS |
Subtitle of host publication | From Biology to Cancer Therapy |
Publisher | Elsevier Inc. |
Pages | 155-174 |
Number of pages | 20 |
ISBN (Electronic) | 9780128035412 |
ISBN (Print) | 9780128035054 |
DOIs | |
State | Published - Jan 1 2017 |
Keywords
- Covalent inhibitor
- G12C
- Irreversible inhibitor
- K
- KRAS
ASJC Scopus subject areas
- Medicine(all)